Medindia

X

NTT DATA Launches First Self-Designed DATATRAK eClinical(TM) Project Into Production in Japan

Friday, November 21, 2008 General News J E 4
Advertisement
CLEVELAND and TOKYO, Nov. 21 DATATRAKInternational, Inc. (Nasdaq: DATA), a technology and services company focusedon global eClinical solutions for the clinical trials industry, today reportedthat its alliance partner in Japan, NTT DATA Corporation, has placed its firstself-designed project using the DATATRAK eClinical platform into productionfor a Japanese clinical trial. The successful rollout of this firstindependently designed clinical trial followed a successful completion of anEnterprise Transfer Program from DATATRAK.

Through DATATRAK's Enterprise Transfer Program, any client can becomeindependent in the rollout of electronic clinical trials with the Company'seClinical platform. At this time, all Enterprise Transfer clients continue tohost their projects through DATATRAK's state-of-the-art global data center;however, because of advancements with the eClinical platform from theDevelopment Team, it will soon be possible for clients to utilize an optionalbusiness approach of hosting their own studies and licensing the product suitefor multi-year periods.

"The strength of the product suite from DATATRAK and their valuableexperience in performing many global clinical trials was critical to thesuccess of our joint efforts with this project for our Japanese customer,"stated Hiroto Ohno, Senior Manager of Healthcare System Sector for NTT DATACorporation. "We look forward to deploying many more electronic clinicaltrials in this market with DATATRAK eClinical."

"Our Team has been working closely with NTT DATA with the goal ofempowering them to be independent with our platform so that both companies cangain increasing traction in the Japanese clinical trial market," stated Dr.Jeffrey A. Green, Chief Executive Officer of DATATRAK International, Inc."This month, the Teams at both companies were successful at accomplishing thismilestone with what turned out to be a very complex clinical trial design.Because of the experiences learned by all, subsequent clinical trialdeployments will be even more efficient in deployment as NTT DATA continues tomake excellent progress in this specific geographic market."

About DATATRAK International

DATATRAK International, Inc. is a worldwide technology company focused onthe provision of multi-component eClinical solutions and related services forthe clinical trials industry. The Company delivers a complete portfolio ofsoftware products that were created in order to accelerate clinical researchdata from investigative sites to clinical trial sponsors and ultimately theFDA, faster and more efficiently than manual methods or loosely integratedtechnologies. DATATRAK's eClinical software suite can be deployed worldwidethrough an ASP offering or in a licensed Enterprise Transfer model that fullyempowers its clients. The DATATRAK software suite and its earlier versionshave successfully supported hundreds of international clinical trialsinvolving thousands of clinical research sites and encompassing tens ofthousands of patients in 59 countries. DATATRAK International, Inc.'s productsuite has been utilized in some aspect of the clinical development of 16 drugsand one device that have received regulatory approval from either the UnitedStates Food and Drug Administration or counterpart European bodies. DATATRAKInternational, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas.Its common stock is listed on the NASDAQ stock Market under the ticker symbol"DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, thestatements made in this release are forward-looking statements. Theseforward-looking statements are made based on management's expectations andbeliefs concerning future events impacting the Company and are subject touncertainties and factors (including those specified below) which aredifficult to predict and, in many instances, are beyond the control of theCompany. Factors that may cause actual results to differ materially from thosein the forward-looking statements include the limited operating history onwhich the Company's performance can be evaluated; the ability of the Companyto continue to enhance its software products to meet customer and marketneeds; fluctuations in the Company's quarterly results; the viability of theCompany's business strategy and its early stage of development; the timing ofclinical trial sponsor decisions to conduct new clinical trials or cancel ordelay ongoing trials; the Company's dependence on major customers; governmentregulation associated with clinical trials and the approval of new drugs; theability of the Company to compete in the emerging EDC market; losses thatpotentially could be incurred from breaches of contracts or loss of customerdata; the inability to protect intellectual property rights or theinfringement upon other's intellectual property rights; the Company's successin integrating its acquisition's operations into its own operations and thecosts associated with maintaining and/or developing two product suites; andgeneral economic conditions such as the rate of employment, inflation,interest rates and the condition of capital markets. This list of factors isnot all inclusive. In addition, the Company's success depends on the outcomeof various strategic initiatives it has undertaken, all of which are based onassumptions made by the Company concerning trends in the clinical researchmarket and the health care industry. The Company undertakes no obligation toupdate publicly or revise any forward-looking statement.

SOURCE DATATRAK International, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Cyntellect Appoints Former BD Biosciences Executiv...
S
Compressus' Next Generation MEDxConnect(TM) Intero...